Canada Biogenix
canadabiogenix.com
Email me when this record changes
Following this record emails you when it gains a dated entry or its published claims are re-read, and nothing about any other supplier. No topic below is ticked: tick one only if you also want it in the same email.
Compiled automatically from the dated observations in this vendor's record. How we evaluate.
Never merged into one number. Some supplier links here are referral links, marked where they appear, which pay Terminus Research when a reader buys. The same terms are open to every supplier in the ledger, apart from the one exception the referral policy page names, participation changes no score, rank, caution, or coverage decision, and a link is not an endorsement.
Canada Biogenix's retatrutide 10mg certificate, hosted at testides.com under report code CBI-RETA-10-040826, shows 99.73 percent purity by HPLC-UV at 214 nm and 11.35 mg against the 10mg label, with the client and vendor fields both reading Canada Biogenix despite a sitewide banner calling the documents "THIRD-PARTY COA REPORTS". That same 10mg-coded report is linked from the separately priced 20mg retatrutide page, and the pattern repeats for MOTS-C, where all three sizes link one identical certificate, and for GHK-Cu, where both sizes share one document, each mismatch traceable because the site's own certificate codes name a strength figure. The site's Our Story page ties a personal account of a parent's cancer diagnosis to the retatrutide catalog listing by name, and a "Cancer Research" category page sells fenbendazole and methylene blue with no certificate link on any listing, and two product badges there read "Pharma grade" with no compendial reference, registration number or facility named behind them. Has anyone who bought the 20mg retatrutide vial, or the 40mg MOTS-C or 100mg GHK-Cu sizes, checked whether the certificate that shipped matched the vial's actual strength instead of the smaller-dose document linked online?
What the record holds
NO FIRM COMMITMENT
“regional delivery windows are estimated at one to three business days for Ontario and Quebec, three to five for Western Canada and five to seven for Atlantic Canada and the territories”
Published at /shipping-policy/: Canada-only, no international service, with a visitor outside Canada invited to contact the vendor directly. The windows quoted are regional delivery estimates, not a dispatch or processing commitment, so the weaker class applies. The free-shipping threshold is stated only in the sitewide banner (FREE SHIPPING OVER $250); the policy page repeats that a threshold exists without restating the figure. 48-hour reporting window for damaged-package claims, 5 to 10 business day refund-processing estimate.
Read from this supplier's own pages on 2026-08-26. This publication has never placed an order with any supplier. This row records what is written and measures nothing about what actually happens after an order.
Compound retatrutide 10mg
Listed as Retatrutide 10 mg, single vial, on its own dedicated product page
Price as recorded priced only in Canadian dollars, never a bare numeral on the page: ninety dollars even for the single ten-milligram vial, ten in stock, against one hundred thirty dollars for the sibling Retatrutide twenty-milligram vial, both read live from the product pages and matching the homepage's featured-products grid
Read on 2026-08-26. One reading on one day, and prices are not tracked over time here.
This supplier was not part of the Trustpilot reading of 2026-08-25, which covered 59 of the 126 suppliers on file. That is a fact about this publication's coverage, stated rather than left to be read either way.
6 claims from this publication's own dossier on this supplier were read again against the live site on 2026-08-26: 1 held, 5 corrected before publication.
A corrected claim is an error of ours that the re-read caught before it reached a page. This line tracks this publication's own accuracy. It says nothing about the supplier.
Dated entries
5 observations on file, recorded 2026-08-26. Newest first, appended and never rewritten.
Certificates are linked per product from the shop grid and from each product page's own add-to-cart panel as a COA REPORT anchor pointing out to testides.com/report/..., with no stand-alone certificate index on this domain. Reading the live product-sitemap.xml (53 product URLs at a re-read late on 2026-08-26; an earlier read the same day had returned 51, so the file moves intraday) against the /shop/ archive and the homepage's featured grid on 2026-08-26, thirteen distinct testides.com report codes are in circulation, covering Retatrutide, BPC-157, TB-500, GHK-Cu, MOTS-C, CJC-1295 plus Ipamorelin, Ipamorelin alone, Tesamorelin, SS-31, Semax, Epitalon and both Melanotan variants; the remaining products, including 5-AMINO-1MQ, Wolverine, Tirzepatide, NAD, Kisspeptin-10, Thymosin Alpha-1, Thymulin, PNC-27, the two fenbendazole listings, methylene blue, glutathione, oxytocin, KPV, DSIP, VIP, Klow, Glow, epitalon's neighbours in the growth-hormone group, the nicotine patches and every bacteriostatic-water and supply SKU, carry no certificate link anywhere on the site as fetched today. I opened the Retatrutide 10 mg certificate in full at testides.com/report/CBI-RETA-10-040826: report number CBI-RETA-10-040826, peptide name Retatrutide, method stated on the face as HPLC-UV at 214 nm, appearance white lyophilized powder, client Canada Biogenix, vendor Canada Biogenix, batch and lot both 0409, an April 8 2026 date the HTML report view labels Test Date but the certificate PDF itself labels Date Requested, then sample received April 14 2026, tested April 19 2026, reported April 20 2026, an ordinary request-to-report sequence once the PDF's own field names are used; the label disagreement between the lab's HTML view and its own PDF for that April 8 field is the residual oddity, re-read from both renderings, purity 99.73 percent, amount 11.35 mg against a 10 mg label. That same report code is the one linked from the Retatrutide 10 mg product page. The Retatrutide 20 mg page, priced separately as its own SKU, links that identical CBI-RETA-10-040826 report rather than a 20 mg-scaled document, so a buyer of the 20 mg vial is shown a certificate for an 11.35 mg finding under a 10 mg code. This is not an isolated mismatch: I opened the three MOTS-C size variants, 10 mg, 20 mg and 40 mg, and all three link the identical CBI-MOTS-10-012326 report, and I opened both GHK-Cu listings, titled GHK-CU 50 mg and GHK-CU 100 mg, and both link the identical CBI-GHK-Cu-50-070626 report. The site's own certificate-code convention embeds a strength figure in the code (RETA-10, MOTS-10, GHK-Cu-50), and every non-matching size variant of those three compounds is sold against a certificate whose own code names a different amount than the vial it is attached to.
On the laboratory. The sitewide banner strip does not name the certificate host; its testing badge reads "THIRD-PARTY COA REPORTS", and the host is identified only by each product's own COA REPORT link pointing at testides.com. testides.com resolves live today to a page titled "Testides - Client Portal", a single-page application shell (the served document is an empty #root div plus a bundled script, and that response carries no content-security-policy header at all; the strict policy whose script-src reads 'none' is set instead on the server-rendered /report/ documents, which carry no script of their own to restrict, re-confirmed against both responses' headers today) rather than a static marketing site. I pulled that bundle, assets/index-hhNAsAHM.js, directly and read its embedded strings rather than describing the shell: it carries a street address, 4211 Yonge Street, Suite 230, Toronto, ON, a contact address info@testides.com, and a self-description of "ISO 17025-Aligned" laboratory status, which is alignment language rather than a claim to hold the accreditation; the strings accreditation, A2LA and CLIA do not appear anywhere in the bundle. I exercised the report verification route rather than only describing it: fetching https://testides.com/report/CBI-RETA-10-040826 directly returns the full analytical record server-rendered (report number, peptide name, method, dates, purity, amount, sample photo and chromatogram image references, and a PDF download link), confirmed live on 2026-08-26. A control fetch of an invented code, CBI-RETA-99-999999, returns HTTP 404 with a "Test report not found" page rather than any content, so the lookup is a genuine index rather than a template that renders for any code. Client and vendor both print as Canada Biogenix on the retatrutide document, consistent with Canada Biogenix having submitted its own sample rather than the figure being sourced from a third party's earlier submission.
Benchmark and catalog read live from the product pages on 2026-08-26. Pricing on this site is Canadian dollars only, and every page marks it explicitly with a CA prefix ahead of the currency symbol rather than a bare figure: the Retatrutide 10 mg page prices the single vial at ninety dollars even, ten in stock, and the Retatrutide 20 mg page prices its vial at one hundred thirty dollars, seventeen in stock at the first read and twenty at a re-read later the same day, a figure that moves with orders, both confirmed against the same figures repeated in the homepage's featured-products grid. The catalog holds 53 product URLs in product-sitemap.xml as re-read late on 2026-08-26 (51 at the first read that day), spanning peptides, two fenbendazole-based items, nicotine patches, insulin syringes, alcohol pads and four bacteriostatic-water pack sizes; there is no kit structure anywhere on the site, every listing is a single vial or single pack sold by unit quantity with no multi-vial bundle pricing. A sitewide banner strip, present on the homepage and on category archives, rotates four fixed phrases, re-read verbatim from the live pages on 2026-08-26: "FREE SHIPPING OVER $250", "SECURE CREDIT CARD & E-TRANSFER", "CANADIAN-OWNED & OPERATED" (the /peptides/ page carries a variant pairing "CANADIAN-OWNED" with "SELECT PEPTIDES MADE IN CANADA") and "THIRD-PARTY COA REPORTS", the last a stronger independence claim than the certificates themselves support, since the retatrutide certificate hosted at testides.com prints Canada Biogenix in both its Client and Vendor fields. The dedicated /shipping-policy/ page adds that shipping is Canada-only with no international service offered, that a visitor outside Canada is invited to contact the vendor directly, and that regional delivery windows are estimated at one to three business days for Ontario and Quebec, three to five for Western Canada and five to seven for Atlantic Canada and the territories; it repeats that a free-shipping threshold exists without restating the dollar figure, leaving the $250 number to the banner alone. /refund_returns/ states all sales are final upon delivery outside a narrow list of exceptions (visibly damaged in transit, wrong item shipped, lost and confirmed undeliverable, or an order the vendor could not fulfil), a 48-hour reporting window for a damaged-package claim, and a 5 to 10 business day refund-processing estimate. Research-use-only framing appears in a persistent footer banner on every page reading that the materials are not approved by Health Canada for cosmetic application, therapeutic use, injection, ingestion or any human or animal use, and the terms page sets the site's age gate at 18, not 21.
On entity and contact detail, and it is thin. No street address appears anywhere I fetched, on the homepage, the shop, the four policy pages or the Our Story page. No telephone number appears anywhere either. No legal entity suffix (Inc., Ltd., Corp.) is used; the brand name alone, styled inconsistently as both "Canada Biogenix" and "CanadaBioGenix" across different pages, stands in for a company name throughout. Contact is split across three different addresses depending on which page a visitor lands on: sales@canadabiogenix.com is used in the footer, on the Our Story page and as the refund-request address; support@canadabiogenix.com is used on the shipping and privacy policy pages; and the terms-and-conditions page's own dedicated contact line names a fourth, different address again, a plain Gmail address rather than one on the company's own domain. The privacy policy states PIPEDA compliance and a 30-day response commitment for a data request, addressed to the support@ address.
CAUTIONCautions noted. First, the site's Our Story page carries an extended first-person narrative describing why the founders began sourcing these compounds: a parent's diagnosis with a blood cancer and another parent's diagnosis with a gastrointestinal stromal tumour, framed as the reason the founders investigated repurposed compounds and the peptide catalog that followed. The same page goes on to describe personal outcomes the founders or people close to them attribute to using the site's own catalog, including a named body-weight figure attached to Retatrutide by name and a account of infections resolving unusually quickly, phrased as first-person testimony rather than as sourced clinical evidence. The page does carry a disclaimer stating that personal accounts are anecdotal, are not evidence of the two qualities a research-use disclaimer normally names, and are not medical advice, but the narrative content sits well upstream of that disclaimer and names the flagship compound directly inside the personal account. Second, the Retatrutide 10 mg product page carries an extensive body of human clinical-trial framing rather than research-use description: named Phase 2 and Phase 3 trial acronyms, percentage figures for body-weight change, glycemic and liver-fat measures attributed to each named trial, a head-to-head comparison table against semaglutide and tirzepatide, and a cited reading list whose entries include one external blog title that names the banned two-word body-composition outcome phrase directly in its own title text. Third, the product catalog includes a dedicated cancer-framed category page, titled "Cancer Research" in both its title tag and its on-page heading (the "cancer-support" wording survives only in the URL slug, and a companion anchor section on /peptides/ is titled "Cancer & Immune Research"), populated with fenbendazole (both alone and combined with ivermectin), methylene blue, glutathione, KPV, PNC-27 tagged "Oncology Research", and Thymosin Alpha-1 and Thymulin tagged "Immune Support", none of which carry a certificate link on that category page. Fourth, two product badges read "Pharma grade" on that same category archive, an unqualified manufacturing-standard claim with no compendial reference, registration number or facility named anywhere behind it. Fifth, as detailed above, the Retatrutide 20 mg, MOTS-C 20 mg, MOTS-C 40 mg and GHK-CU 100 mg listings each display a certificate whose own code names a different strength than the vial being sold, so the certificate a buyer is shown does not correspond to the labelled amount in three of the four cases examined. Sixth, the site publishes a Dosage Calculator as a primary navigation item alongside the shop; its output could not be read from a static fetch since the tool renders client-side, but the page's existence and placement is itself notable next to a storefront selling the compounds it would presumably calculate for.
Reader reviews
No reader review of this supplier is published yet. Every review is read and checked against the record before it appears. Add a review.
Open this supplier
Some supplier links here are referral links, marked where they appear, which pay Terminus Research when a reader buys. The same terms are open to every supplier in the ledger, apart from the one exception the referral policy page names, participation changes no score, rank, caution, or coverage decision, and a link is not an endorsement.